Antiprotozoal/Antiparasitic Agents

P. Woster
{"title":"Antiprotozoal/Antiparasitic Agents","authors":"P. Woster","doi":"10.1002/0471266949.BMC235","DOIUrl":null,"url":null,"abstract":"Collectively, diseases caused by parasitic protozoa, including human African trypanosomiasis (HAT), Chagas' disease and leishmaniasis, threaten more than 550 million people worldwide and cause nearly 150,000 deaths annually. The causative organisms for these diseases are unicellular trypanosomatid parasites of the genera Trypanosoma brucei, Trypanosoma cruzi, and Leishmania sp., respectively. Drug therapies available for these diseases have not changed significantly in the past 50 years, and currently used agents are far less than satisfactory due to extreme toxicity, and because resistant parasitic strains are becoming more prevalent. These diseases are confined to impoverished or rural areas of Mexico, Central America, South America, sub-Saharan Africa, the Middle East, Indonesia, and India. As such, drug discovery efforts against trypanosomatid diseases are limited because patients in underdeveloped areas cannot afford therapy, and because the infected population is too small to justify the required research expenditures. In addition, antiparasitic research in Third World nations is often hampered by economic issues and political turmoil, virtually assuring that the world's most impoverished people will continue to bear the major burden of parasitic disease. Clearly, there is a need for new anti-infective agents that are potent, nontoxic and inexpensive to manufacture. In this chapter, the etiology of these diseases and their current treatment are described. The chapter also deals with medicinal chemistry aspects of efforts to identify new drug targets for parasitic diseases, and to produce novel inhibitors of trypanosomatid growth for use as antiparasitic agents. \n \n \nKeywords: \n \namidine; \nantiparasitic; \nChaga's disease; \nchemotherapy; \ncutaneous leishmaniasis; \ncysteine protease; \nglucose metabolism; \nglucose transport; \nglycosome; \nguanidine; \nhuman African trypanosomiasis; \nLeishmania donovani; \nlife cycle; \nlipid metabolism; \nnucleotide transporter; \npolyamines; \nprotozoa; \nTrypanosoma brucei; \nTrypanosoma cruzi; \nvisceral leishmaniasis","PeriodicalId":9514,"journal":{"name":"Burger's Medicinal Chemistry and Drug Discovery","volume":"33 1","pages":"563-600"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Burger's Medicinal Chemistry and Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/0471266949.BMC235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Collectively, diseases caused by parasitic protozoa, including human African trypanosomiasis (HAT), Chagas' disease and leishmaniasis, threaten more than 550 million people worldwide and cause nearly 150,000 deaths annually. The causative organisms for these diseases are unicellular trypanosomatid parasites of the genera Trypanosoma brucei, Trypanosoma cruzi, and Leishmania sp., respectively. Drug therapies available for these diseases have not changed significantly in the past 50 years, and currently used agents are far less than satisfactory due to extreme toxicity, and because resistant parasitic strains are becoming more prevalent. These diseases are confined to impoverished or rural areas of Mexico, Central America, South America, sub-Saharan Africa, the Middle East, Indonesia, and India. As such, drug discovery efforts against trypanosomatid diseases are limited because patients in underdeveloped areas cannot afford therapy, and because the infected population is too small to justify the required research expenditures. In addition, antiparasitic research in Third World nations is often hampered by economic issues and political turmoil, virtually assuring that the world's most impoverished people will continue to bear the major burden of parasitic disease. Clearly, there is a need for new anti-infective agents that are potent, nontoxic and inexpensive to manufacture. In this chapter, the etiology of these diseases and their current treatment are described. The chapter also deals with medicinal chemistry aspects of efforts to identify new drug targets for parasitic diseases, and to produce novel inhibitors of trypanosomatid growth for use as antiparasitic agents. Keywords: amidine; antiparasitic; Chaga's disease; chemotherapy; cutaneous leishmaniasis; cysteine protease; glucose metabolism; glucose transport; glycosome; guanidine; human African trypanosomiasis; Leishmania donovani; life cycle; lipid metabolism; nucleotide transporter; polyamines; protozoa; Trypanosoma brucei; Trypanosoma cruzi; visceral leishmaniasis
Antiprotozoal /抗寄生虫药物
由寄生原生动物引起的疾病,包括非洲人类锥虫病、南美锥虫病和利什曼病,每年威胁着全世界5.5亿多人,造成近15万人死亡。这些疾病的致病生物分别是布鲁氏锥虫属、克氏锥虫属和利什曼原虫属的单细胞锥虫寄生虫。在过去的50年里,这些疾病的现有药物治疗没有发生重大变化,目前使用的药物远远不能令人满意,因为毒性极大,而且因为耐药的寄生虫菌株越来越普遍。这些疾病局限于墨西哥、中美洲、南美洲、撒哈拉以南非洲、中东、印度尼西亚和印度的贫困或农村地区。因此,针对锥虫病的药物发现工作是有限的,因为不发达地区的患者负担不起治疗费用,而且因为受感染的人口太少,不足以证明所需的研究支出是合理的。此外,第三世界国家的抗寄生虫研究往往受到经济问题和政治动荡的阻碍,几乎可以肯定,世界上最贫困的人民将继续承受寄生虫病的主要负担。显然,我们需要一种强效、无毒且生产成本低廉的新型抗感染药物。在这一章,这些疾病的病因和他们目前的治疗描述。本章还涉及药物化学方面的努力,以确定新的药物靶点寄生虫疾病,并产生新的抑制剂锥虫生长用作抗寄生虫剂。关键词:脒;杀寄生虫药;白桦茸的疾病;化疗;皮肤利什曼病;半胱氨酸蛋白酶;葡萄糖代谢;葡萄糖运输;glycosome;胍;非洲人类锥虫病;杜氏利什曼虫;生命周期;脂质代谢;核苷酸运输车;多胺;原生动物;锥虫属brucei;鲁兹锥体;内脏利什曼病
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信